問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Psychiatry

更新時間：2023-09-19

楊延光Yang, Yen-Kwuan
  • Principal Investigator
  • Clinical Trial Experience (year) 23 years 9 個月

Recruiting Trial

8Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

楊延光

List

44Cases

2014-06-01 - 2018-09-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2010-12-01 - 2014-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2010-12-01 - 2014-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2012-05-01 - 2014-12-31

Phase II/III

  • Condition/Disease

  • Test Drug

Participate Sites
14Sites

Terminated14Sites

2012-05-01 - 2013-12-31

Phase II/III

  • Condition/Disease

  • Test Drug

Participate Sites
14Sites

Terminated14Sites

2010-07-07 - 2013-06-08

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Terminated10Sites

2013-12-18 - 2015-10-31

Phase III

A Multicenter, Randomized, Double-blind Trial to Assess the Efficacy and Safety of ASC-01 in Patients with Major Depressive Disorder

  • Condition/Disease

    Major depressive disorder

  • Test Drug

    ASC-01

Participate Sites
12Sites

Terminated12Sites

藍先元
China Medical University Hospital

Division of Psychiatry

2019-09-01 - 2022-09-22

Phase III

A double-blind, placebo-controlled,randomized withdrawal, multicenter clinical trial evaluating the efficacy, safety, and tolerability of cariprazine in a dose-reduction paradigm in the prevention of relapse in bipolar I disorder patients whose current episode is manic or depressive, with or without mixed features

  • Condition/Disease

    Bipolar I disorder

  • Test Drug

    Cariprazine

Participate Sites
5Sites

Not yet recruiting1Sites

Recruiting4Sites

2019-10-01 - 2021-01-26

Phase III

A double-blind, placebo-controlled, randomized withdrawal, multicenter clinical trial evaluating the efficacy, safety, and tolerability of cariprazine in a dose-reduction paradigm in the prevention of relapse in patients with schizophrenia.

  • Condition/Disease

    Schizophrenia

  • Test Drug

    Cariprazine

Participate Sites
3Sites

Not yet recruiting2Sites

Study ended1Sites

2019-08-01 - 2021-04-14

Phase II

A phase II randomised, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of orally administered BI 409306 during a 28-week treatment period as adjunctive therapy to antipsychotic treatment for the prevention of relapse in patients with schizophrenia.

  • Condition/Disease

    Schizophrenia

  • Test Drug

    BI 409306

Participate Sites
4Sites

Terminated3Sites

Study ended1Sites

1 2 3 4 5
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB